We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ACN00177

News List

Aeglea Receives FDA Rare Pediatric Disease Designation for Homocystinuria Treatment americanpharmaceuticalreview
December 22, 2020
Aeglea BioTherapeutics announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to ACN00177 for the treatment of Homocystinuria, a serious metabolic disorder characterized by elevated plasma homocysteine ...
Aeglea BioTherapeutics Announces Orphan Drug Designations for Homocystinuria americanpharmaceuticalreview
October 30, 2020
Aeglea BioTherapeutics announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ACN00177 for the treatment of Homocystinuria, a serious metabolic disorder characterized by elevated plasma homocysteine which leads to ...